BIO-key sees 2025 growth with 20% higher license revenue and enhanced focus on proprietary solutions
Q4 2024 Management View CEO Michael DePasquale highlighted a transition in BIO-key's business strategy, focusing exclusively on proprietary solutions like PortalGuard IAM and Identity-Bound Biometrics ...
Real Business Solutions Innovates Small Business Funding with Expert Consulting and Proprietary Financing Technology
WILMINGTON, DE / ACCESS Newswire / March 25, 2025 / Real Business Solutions is a trusted provider of professional financial ...
HousingWire6d
Onity leaders talk reverse channel profitability, tease proprietary product development
Onity Group executives tout the profitability of their reverse mortgage business and tease the development of a new private-label offering.
Horizon Kinetics Holding Corporation Reports Fourth Quarter and Annual Results
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Horizon Kinetics Holding Corporation (the "Company" or "HKHC") (OTC PINK:HKHC) reported financial results for its fourth quarter and year ended ...
Yahoo Finance1mon
Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study
which determines consumer comprehension of its unique messaging within its proprietary Technology. In the study, the Company's technology facilitated consumer's understanding of designated ...
Morningstar7d
Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology
Proprietary sensing and ablation technology ... (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases ...
Morningstar8d
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
has conditionally accepted the Company’s new proprietary name, REYOBIQ™, for its lead therapeutic candidate. A request for proprietary name review for REYOBIQ™ must be submitted once the ...
manilatimes23d
PathMaker Neurosystems Announces Issuance of Three Patents Protecting the Use of Company's Proprietary Neuromodulation Technology in ALS
PathMaker's approach is based on the company's proprietary multi-site direct current stimulation (Multi-Site DCS) platform, which modulates neurons and circuits associated with ALS through the ...